연구성과로 돌아가기

2021 연구성과별 연구자 정보 (201 / 2991)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Aqueous Nd³⁺ capture using a carboxyl-functionalized porous carbon derived from ZIF-8 Bhattacharjee, Samiran Bhattacharjee, S 2 Univ Dhaka, Ctr Adv Res Sci CARS, Dhaka 1000, Bangladesh 0000-0002-9528-6552 BHATTACHARJEE, SAMIRAN rhadum@cnu.ac.kr;whasahn@inha.ac.kr;
Aqueous Nd³⁺ capture using a carboxyl-functionalized porous carbon derived from ZIF-8 Lee, Chang-Soo Lee, CS 3 교신저자 Chungnam Natl Univ, Dept Chem Engn & Appl Chem, Daejeon 305764, South Korea HME-1129-2023 Lee, Chang rhadum@cnu.ac.kr;whasahn@inha.ac.kr;
Aqueous Nd³⁺ capture using a carboxyl-functionalized porous carbon derived from ZIF-8 Kang, Kyoung-Ku Kang, KK 4 Chungnam Natl Univ, Dept Chem Engn & Appl Chem, Daejeon 305764, South Korea HLX-0854-2023 Kang, Kyoung-Ku rhadum@cnu.ac.kr;whasahn@inha.ac.kr;
Aqueous Nd³⁺ capture using a carboxyl-functionalized porous carbon derived from ZIF-8 Ahn, Ji-Whan Ahn, JW 5 Korea Inst Geosci & Mineral Resources KIGAM, Daejeon 305350, South Korea rhadum@cnu.ac.kr;whasahn@inha.ac.kr;
Aqueous Nd³⁺ capture using a carboxyl-functionalized porous carbon derived from ZIF-8 Ahn, Wha-Seung Ahn, WS 6 교신저자 Inha Univ, Dept Chem & Chem Engn, Incheon 402751, South Korea rhadum@cnu.ac.kr;whasahn@inha.ac.kr;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Yen, Ivana Yen, I 1 Genentech Inc, Dept Discovery Oncol, San Francisco, CA 94080 USA twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Shanahan, Frances Shanahan, F 2 Genentech Inc, Dept Discovery Oncol, San Francisco, CA 94080 USA twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Lee, Jeeyun Lee, J 3 Sungkyunkwan Univ, Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea C-9646-2011 Lee, Jee twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Lee, Jeeyun Lee, J 3 Sungkyunkwan Univ, Samsung Med Ctr, Dept Intelligence Precis Healthcare Convergence, Sch Med, Suwon, South Korea C-9646-2011 Lee, Jee twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Hong, Yong Sang Hong, YS 4 Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Shin, Sang Joon Shin, SJ 5 Yonsei Univ, Dept Internal Med, Div Med Oncol, Coll Med, Seoul, South Korea 0000-0001-5350-7241 Shin, Sang Joon twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Moore, Amanda R. Moore, AR 6 Genentech Inc, Dept Discovery Oncol, San Francisco, CA 94080 USA twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Sudhamsu, Jawahar Sudhamsu, J 7 Genentech Inc, Dept Discovery Oncol, San Francisco, CA 94080 USA 0000-0003-0737-2299 Sudhamsu, Jawahar twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Sudhamsu, Jawahar Sudhamsu, J 7 Genentech Inc, Dept Struct Biol, San Francisco, CA 94080 USA 0000-0003-0737-2299 Sudhamsu, Jawahar twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Chang, Matthew T. Chang, MT 8 Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA twkimmd@amc.seoul.kr;shivam@gene.com;
페이지 이동: